Infection with hepatitis C virus (HCV), a leading cause of chronic liver diseases, can associate with B lymphocyte proliferative disorders, such as mixed cryoglobulinemia and non-Hodgkin lymphoma. The major envelope protein of HCV (HCV-E2) binds, with high affinity CD81, a tetraspanin expressed on several cell types. Here, we show that engagement of CD81 on human B cells by a combination of HCV-E2 and an anti-CD81 mAb triggers the JNK pathway and leads to the preferential proliferation of the naïve (CD27 ؊ ) B cell subset. In parallel, we have found that B lymphocytes from the great majority of chronic hepatitis C patients are activated and that naïve cells display a higher level of activation markers than memory (CD27 ؉ ) B lymphocytes. Moreover, eradication of HCV infection by IFN therapy is associated with normalization of the activation-markers expression. We propose that CD81-mediated activation of B cells in vitro recapitulates the effects of HCV binding to B cell CD81 in vivo and that polyclonal proliferation of naïve B lymphocytes is a key initiating factor for the development of the HCV-associated B lymphocyte disorders.
H
epatitis C virus (HCV) is a positive-stranded RNA virus of the Flaviviridae family (1) . The HCV genome is 9.6 kb in length, with one large translational ORF encoding a single polyprotein, which is processed by host and viral proteases into at least three structural and seven nonstructural proteins with various enzymatic activities (1) . Two heavily N-glycosylated proteins E1 and E2 are virion-envelope proteins and form heterodimers in vitro (2) . An estimated 170 million individuals are infected with HCV worldwide (3) . HCV infection is associated with the development of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (4) . B cell abnormalities, including cryoglobulinemia (5) and an increased risk of B cell non-Hodgkin lymphoma (6, 7) , have been reported in a minority of HCV infections.
Until very recently, it was not possible to grow HCV in cell culture, therefore studies of virus interaction with human cells have been surrogated by the assessment of binding and entry of HCV recombinant glycoproteins (8) or virus pseudotypes (9) .
We have previously reported that HCV-E2 protein binds with high affinity to the large extracellular loop of human CD81 (CD81-LEL) and that ''bona fide'' HCV particles bind human CD81 (10) . Recently, it has been demonstrated that CD81 is required for entry and infection of human cells by in vitro-generated infectious HCV (11) . CD81 is a widely distributed cell-surface tetraspanin that participates in different molecular complexes on various cell types, including B, T, and natural killer (NK) cells (12) . On human B cells, CD81 is known to form a costimulatory complex with CD19 and CD21 (13, 14) and that coligation of the B cell antigen receptor (BCR) with any of the components of this costimulatory complex lowers the threshold required for BCR-mediated B cell proliferation (15) . We have proposed that HCV exploits CD81 not only to invade hepatocytes but also to modulate the immune system. Indeed, cross-linking of CD81 by the HCV-E2 protein or anti-CD81 mAbs leads to costimulation of human T cells (16) or inhibition of human NK cells (17) . In this study, we investigated whether engagement of CD81 by recombinant HCV-E2 protein and͞or anti-CD81 mAbs had any effect on human B cell function. We found that multimeric engagement of CD81 activates B lymphocytes in the absence of BCR coligation. At variance with other B cell polyclonal stimuli, CD81 engagement preferentially induced proliferation of naïve B cells. We also found that, in the great majority of HCV-infected patients, B cells display an activated phenotype that disappears after therapeutic eradication of HCV.
Materials and Methods
Patients. We analyzed peripheral blood B lymphocytes from 64 patients (55% males and 45% females; median age of 62.5 years) with chronic HCV infection, as demonstrated by the presence of HCV-RNA and elevated serum levels (Ͼ40 units͞liter) of alanine aminotransferase. Most of the patients (61%) were infected with HCV genotype 1; the remainder (39%) were infected by genotypes 2 and 3. A fraction of these patients (26 of 64) were diagnosed with cryoglobulinemia, as indicated by the presence of dosable levels of cryoglobulins (Ͼ1.0%) accompanied by weakness, arthralgias, and purpura (see Table 3 , which is published as supporting information on the PNAS web site). Patients were therapy-naïve or had been off antiviral therapy for Ͼ12 months at the time of the sampling. None of them had clinical evidence of cirrhosis.
Twenty-two of 64 subjects were selected among therapy-naïve patients and underwent antiviral therapy. Patients received 1.5 g of peginterferon ␣-2b (PEG-Intron, Shering-Plough) per kg of body weight s.c. once weekly and oral ribavirin (Rebetol, SheringPlough) at 1,000-1,200 mg͞day (those weighing Ͼ75 kg received the higher dose). Treatment lasted 6 months for patients with genotypes 2 and 3 (13 of 22) and 12 months for patients with genotype 1 (9 of 22). Analyses were performed before and at the end of therapy. In responders to therapy, as indicated by HCV-RNA negativity at PCR, an additional analysis after 12 months of follow-up was performed to identify patients who achieved sustained virological response. The main biochemical and virological characteristics of HCV-infected patients at the moment of enrollment are summarized in Table 3 . Twenty-one healthy blood donors and 16 patients with chronic hepatitis B, matched for age and sex, were used as control groups. Study protocols were approved by the ethical committee of Trieste University School of Medicine.
All subjects provided written informed consent.
Clinical Tests. Alanine aminotransferase was measured by using standard clinical tests. HCV RNA was determined by using RT-PCR by Amplicor HCV assay (Roche Diagnostics) and quantified with a REAL QUANT C kit (Genedia, Munich). HCV genotypes were determined by using the line-probe assay (Inno-Lipa HCV, Innogenetics, Ghent, Belgium). To evaluate the presence of cryoglobulins, blood samples were allowed to clot at 37°C; serum was centrifuged for 10 min at 350 ϫ g at 4°C in graduated Wintrobe tubes, and the volume percent of the precipitate compared with the total volume of serum (cryocrit) was calculated. Rheumatoid factor was measured by rate nephelometry. ) and memory (CD27 ϩ ) subsets were sorted by FACSVantage SE (Becton Dickinson) with Ͼ96% purity. Human tonsils were obtained from patients undergoing routine tonsillectomy, and B lymphocytes were negatively isolated by using magnetic beads coated with an anti-CD2 mAb (Dynabeads, Oxoid, Basingstoke, U.K.). More than 97% of the isolated cells expressed CD19.
Generation of mAbs Specific for Human CD81-LEL. Monoclonal antibodies (MG81 and N81, IgG1 isotype) were obtained in our laboratory from BALB͞c mice immunized with a recombinant human CD81-LEL fused with thireodoxin (10) by using standard technique. Hybridoma supernatants were screened for the ability to bind human CD81 and to neutralize the binding of HCV-E2 protein to CD81 on CD81-transfected NIH 3T3 cell line (American Type Culture Collection). The F(abЈ) 2 fragments were prepared by pepsin digestion by using the ImmunoPure F(abЈ) 2 kit (Pierce) according to the manufacturer's instructions. Retention of the ability of the F(abЈ) 2 fragment of N81 and MG81 mAbs to bind CD81 on the cell surface was confirmed by flow cytometry.
Cell Cultures and Reagents. All cultures were performed in RPMI medium 1640 (GIBCO͞BRL) supplemented with vitamin, streptomycin, and glutamine, all from GIBCO͞BRL and 10% FCS (HyClone) and incubated at 37°C in a humidified atmosphere containing 5% CO 2 . For the immunoglobulin-secretion experiment, complete medium containing 5% of ultralow IgG FCS (GIBCO͞BRL) was used.
Cells were stimulated in vitro with the following reagents: anti-CD81 mAbs, N81 and MG81; F(abЈ) 2 Carboxyfluorescein Succinimidyl Ester (CFSE) Labeling. Purified naïve and memory B lymphocytes were resuspended at 2 ϫ 10 7 cells per ml in PBS, and CFSE (Molecular Probes) was added at a final concentration of 0.5 M (19). The CFSE-labeled cells were incubated with complete medium, anti-CD81 mAbs (MG81 and N81), or SAC for 96 h, stained with PE-anti-CD27, and analyzed by flow cytometry by using FACSCalibur (Becton Dickinson). Cell viability was measured by propidium iodide incorporation.
In Vitro Ig Production. For Ig measurements, 1 ϫ 10 6 purified naïve and memory B lymphocytes were cultured with CD81 mAbs (MG81 and N81) or SAC. At day 10, IgM and IgG concentration in culture supernatants were measured by standard ELISA techniques, as described in ref. 20 .
Western Blot Analysis. B lymphocytes purified from human tonsils (30 ϫ 10 6 cells per ml) were stimulated with of MG81 (5 g͞ml) and N81 (5 g͞ml) antibodies or goat anti-human IgM F(abЈ) 2 fragments (IgM) (10 g͞ml) at 37°C. At the indicated time, cells were washed with cold PBS and lysed for 1 h on ice in 300 mM NaCl, 50 mM Tris⅐HCl (pH7.6), 1% Triton X-100, 1 mM NaF, 1 mM Na 3 OV 4 , 10 mM sodium pyrophosphate, 1 mM PMSF, and 1ϫ EDTA-free complete protease-inhibitor mixture (Roche Diagnostics). Equal amounts of protein extracts were resolved on 10% SDS͞PAGE gel and transferred on nitrocellulose membrane. Blotting was performed by using horseradish-peroxidase-conjugated 4G10 anti-phosphotyrosine antibody (Upstate Biotechnology, Lake Placid, NY), phospho-c-Jun (KM1) and total c-Jun (H-79) antibodies (Santa Cruz Biotechnology), total CD19 and phospho-CD19 (Tyr-531) antibodies (Cell Signaling Technology, Beverly, MA), phospho JNK1 and -2 (pTpY183͞185), and total JNK1 (BioSource International, Camarillo, CA). The JNK inhibition experiments were conducted by preincubating tonsil-derived B cells for 10 min at 37°C with increasing concentrations of SP600125 (Calbiochem) or an equivalent amount of DMSO as control.
Statistical Analysis. Comparison of the percentages of activation markers and CXCR3 on B cells from HCV patients before therapy, at the end of therapy, and at the end of follow-up was performed by using two-tailed P values, Wilcoxson matched-pairs test (INSTAT3, GraphPad).
Results
Multimeric Engagement of CD81 Induces B Cell Activation and Proliferation. It is well documented that CD81 cross-linking by HCV-E2 protein or by anti-CD81 mAbs inhibits NK cells (17) and costimulates T lymphocytes (16) . Therefore, we assessed the effect of CD81 cross-linking on human B lymphocytes. Engagement of CD81 on freshly purified B cells from healthy individuals through HCV-E2 coated on plastic or anti-CD81 mAb cross-linked by anti-mouse antibodies did not affect expression of activation markers, maturation, or proliferation (data not shown). However, when B lymphocytes were cultured for 5 days with a combination of two anti-CD81 mAbs, MG81 and N81, in soluble form, we detected a robust B cell proliferation (Fig. 1A) . Both MG81 and N81 are directed against the recombinant CD81-LEL protein; however, only N81 is capable of neutralizing HCV-E2 binding to CD81. No stimulation of proliferation was detected when B cells were treated with MG81 or N81 alone (data not shown) or combined with mAbs directed against the other components of the B cell coreceptor, CD19 and CD21 (Fig. 1 A) . The stimulation of B cell proliferation was preserved, although to a lesser extent, when N81 was replaced by a recombinant form of the HCV-E2 glycoprotein, whereas HCV-E2 alone did not have any effect (Fig. 1 A) . We found that B cells stimulated with F(abЈ) 2 MG81 and N81 mAbs proliferate as efficiently as cells stimulated with intact immunoglobulins, excluding the involvement of Fc-mediated activities (Fig. 1B) . To further validate that B cell proliferation was mediated by CD81, recombinant CD81-LEL protein was combined with HCV-E2 plus MG81, SAC, or anti-IgM. The proliferation induced by CD81 engagement was strongly inhibited (50% inhibition at 0.25 g͞ml of CD81-LEL), whereas CD81-LEL did not affect SAC or anti-IgM stimulation (Fig. 1C) . The same results were obtained when HCV-E2 was replaced by N81 or when CD81-LEL was substituted with an anti-HCV-E2 mAb, which is known to interfere with the binding of HCV-E2 to CD81 (data not shown).
CD81 engagement resulted in an increased percentage of B cells expressing the early activation marker CD69, the transferrin receptor CD71, and the costimulatory molecule CD86. Similar results were obtained when well characterized polyclonal B cell stimuli (anti-IgM or SAC) were used ( Table 1 ). Table 1 also shows that CXCR3, which is expressed in a small fraction of resting B cells, is up-regulated by anti-CD81 mAbs but not by anti-IgM and SAC. Taken together, these results demonstrate that multimeric engagement of CD81, in the absence of exogenous cytokines and BCR engagement, induces activation, proliferation, and increased expression of CXCR3 molecules on B lymphocytes and that the epitopes involved in HCV binding to target cells are required for this process.
CD81 Engagement Preferentially Activates Naïve B Cell Proliferation.
B lymphocytes can be schematically divided into naïve and memory subsets on the basis of CD27 expression (21) . To better assess the effect of CD81-mediated activation on these B cell subsets, peripheral blood B lymphocytes were separated as CD27 ϩ and CD27 Ϫ cells, labeled with CFSE, and activated by CD81, IgM, or SAC.
We first assessed the proliferative response through CFSE labeling. Fig. 2 shows that naïve and memory B lymphocytes displayed a similar proliferation rate when activated by SAC. In contrast, CD81 engagement resulted in the preferential division of naïve B cells (45% vs. 1% control), with a minor proliferative effect in the memory B cell subset (15% vs. 9% control) (Fig. 2 Top) . In a control experiment, we found no differences in the cell death rate of memory and naïve B cells activated through CD81 engagement (data not shown).
CD81 multimeric engagement and SAC stimulation induced the differentiation of the majority of naïve cells into memory B lymphocytes. In addition, both CD81 and SAC treatments resulted in the up-regulation of activation molecule CD71 in the naïve and memory B cell subsets (Fig. 2 Middle) .
We then measured the concentration of immunoglobulins in Data are shown as percentage of CD19 cells expressing the markers indicated on the left (mean Ϯ SD). B lymphocytes from healthy donors (n ϭ 10) stimulated in vitro for 24 h by using: * , complete medium; †, MG81 mAb (5 g͞ml) ϩ N81 mAb (5 g͞ml); ‡, SAC (1:30,000 vol͞vol); §, Goat anti-human IgM F(abЈ) 2 (10 g͞ml).
culture supernatants from naïve and memory B cells stimulated through CD81 or SAC. As expected, activated naïve B cells did not produce IgG but a low (in the case of SAC) or very low (in the case of CD81) amount of IgM, whereas memory B cells produced a high amount of IgM and IgG in response to SAC activation and a low amount of IgM and IgG in response to the modest CD81 activation (Fig. 2 Bottom) .
In summary, these results demonstrate that, although CD81 engagement up-regulates activation markers in both the naïve and the memory B cell subsets, it promotes a preferential polyclonal expansion of naïve B lymphocytes.
CD81-Mediated Activation of B Cells
Triggers JNK Activity. We next assessed the intracellular signaling events induced by multimeric CD81 engagement on B cells. We found that, in contrast to BCR stimulation by anti-IgM, multimeric CD81 engagement did not result in a significant increase in total tyrosine phosphorylation levels in purified tonsil-derived B cells (Fig. 3A) . Despite the extensive difference observed in the tyrosine phosphorylation pattern, both CD81 and BCR engagement activated the JNK pathway, as shown by the increased phosphorylation of JNK1 and -2 and by the accumulation of the activated form of c-Jun (pJun) 2-4 h after treatment (Fig. 3A) . When B cells from the same experiment were monitored for activation markers and proliferation, we obtained the same results shown in Table 1 and Fig. 1 for PBMC-derived B cells (data not shown). In addition, JNK inhibitor SP600125 (22) abolished both c-jun activation and proliferation of tonsil B cells induced by CD81 engagement (see Fig. 6 , which is published as supporting information on the PNAS web site). Because CD81 is part of the coreceptor complex with CD19, we assessed whether multimeric CD81 engagement could signal through the activation of CD19, which occurs through phosphorylation of its cytoplasmic domain. BCR engagement by anti-IgM stimulated CD19 phosphorylation, whereas CD81 engagement resulted in a transient inhibition of CD19 phosphorylation (Fig.  3B) . The absence of a significant change in tyrosine phosphorylation levels, together with the inhibition of CD19 activity, suggests that CD81-mediated activation of B cells is independent from the B cell receptor and coreceptor complexes. The activation of the JNK pathway, monitored by phospho c-Jun accumulation, was specific for multimeric CD81 engagement (MG81 plus N81) and did not occur when MG81 and N81 mAbs were provided alone (Fig.  3C) . In contrast, the transient dephosphorylation of CD19 was observed in response to both multimeric engagement and N81 alone (Fig. 3C) .
Chronic HCV Infection Associates with B Lymphocyte Activation. We reasoned that polyclonal B cell activation obtained by multimeric CD81 engagement in vitro could mimic what occurs in HCVinfected patients when whole HCV particles bind CD81 on the B cell surface in vivo. To test this hypothesis, we compared the phenotype of peripheral blood B cells from 64 chronic hepatitis C patients with (n ϭ 26) or without (n ϭ 38) cryoglobulinemia with 21 healthy controls and 16 patients with chronic hepatitis B. We found that B cells from the great majority of HCV patients (54 of 64) expressed elevated levels of the activation markers CD69, CD71, and CD86 and of the chemokine receptor CXCR3, whereas B cells from all 16 patients with chronic hepatitis B had the same levels of activation markers and CXCR3 as healthy controls ( Table  2 ). The up-regulation of the activation markers and CXCR3 did not associate with a particular HCV genotype, RNA levels (Table 3) , or the presence of cryoglobulinemia (Table 2 ). In contrast with previous observations showing that the frequency of B cells is higher in HCV patients (23), we found the same percentage of B lymphocytes (CD19 ϩ cells) in healthy controls and HCV-and hepatitis B virus (HBV)-infected patients (data not shown). We then analyzed the relative expression of activation markers and CXCR3 on naïve (CD27 Ϫ ) and memory (CD27 ϩ ) subsets from peripheral B cells of healthy controls and HCV patients. We found more activated naïve and memory B cells in HCV-infected patients than in healthy controls; however, the difference in the frequency of B cells expressing activation markers and CXCR3 between healthy controls and HCV patients was more pronounced in the naïve B cell subset (Fig. 4) . Because CD27-negative cells upregulate CD27 a few days after activation, the presence of a sizeable fraction of CD27-negative cells that expressed activation markers ex vivo suggests that a continuous activation of naïve B cells occurs After the indicated time, equal amounts of protein extracts where subjected to Western blot analysis using anti-phospho-tyrosine 4G10 (pTyr), anti-phospho c-Jun (pJun), anti-phospho JNK1 and -2 (pJNK1 and pJNK2), and anti-total JNK1 (JNK1) antibodies. Protein standards are expressed on the left in kDa. The asterisk indicates an unidentified protein cross-reacting with the anti-phospho JNK1 and -2 antibody. (B) Tonsil-derived B cells were stimulated as described above for the indicated times, and protein extracts were subjected to Western blot analysis using anti-phospho-CD19 (pCD19) and anti-total CD19 (CD19) antibodies. (C) Tonsil-derived B cells were stimulated with 5 g͞ml MG81, 5 g͞ml N81, or 5 g͞ml both MG81 and N81 mAbs. After the indicated time, Western blot analysis was performed by using pJun, anti total c-Jun (Jun), pCD19, and CD19 antibodies. ctr, untreated cells.
during chronic HCV infection. Accordingly, we also found that HCV patients display a higher percentage of memory (CD27 ϩ ) B cells compared with healthy controls and HBV patients ( Table 2) .
In a previous study performed on cryopreserved peripheral blood lymphocytes from patients with chronic HCV infection, activated B cells were not found (23) . We therefore assessed B cell phenotype in peripheral blood from HCV patients on either freshly separated cells or the same samples that had been cryopreserved. Freshly isolated B cells displayed an increased expression of CD69, CD71, CD86, and CXCR3, as described above. In contrast, cryopreserved B cells from the same samples, although viable and responding to polyclonal stimuli, did not display the activated phenotype (see Fig. 7 , which is published as supporting information on the PNAS web site). This finding indicates that assessment of activation markers on human B cells should be performed in freshly isolated rather than cryopreserved peripheral blood lymphocytes.
Eradication of HCV Associates with a Decreased Number of B Cells
Expressing CXCR3 and Activation Markers. To assess whether B cell activation correlates with HCV replication, we investigated the B cell phenotype in 22 patients with chronic HCV infection before and after IFN and ribavirin therapy. We found that, in patients with sustained virologic response (n ϭ 15), eradication of the virus associates with the reduction of the number of B cells expressing activation markers and CXCR3. In this group, the number of B cells expressing CD69, CD71, CD86, and CXCR3 at the end of the therapy was comparable with the levels observed in healthy controls (P Ͻ 0.005). Importantly, in these patients, the same expression pattern persisted for the 12-month follow-up period (Fig. 5 and Table 3 ).
In contrast, in nonresponder patients (n ϭ 7), the percentage of peripheral blood B lymphocytes expressing CD69, CD71, CD86, and CXCR3 did not change significantly before and after the end of the therapy (Fig. 5 and Table 3 ). Altogether, these data establish a correlation between the presence of HCV virus and the upregulation of activation markers and CXCR3 on circulating B cells.
Discussion
We found that engagement of the HCV receptor CD81 activates human B cells in the absence of BCR coligation. CD81-mediated activation differs from other polyclonal B cell stimuli in that it induces preferential proliferation of naïve B cells, whereas anti-IgM and SAC activate naïve and memory B cell proliferation equally well, and CpGs selectively activate memory B cells (24) .
CD81-mediated B cell activation occurred through a combination of two soluble CD81 ligands, the HCV envelope protein E2 and one anti-CD81 mAb. Because a single antibody should be able to induce capping, our finding indicates that membrane reorganization is not the only key to the CD81-mediated B cell activation. The multimeric CD81 engagement required for activation of B cells is in apparent contrast with the requirement of a single CD81 ligand and a cross-linking agent in CD81-mediated inhibition of NK cells (17) and costimulation of T lymphocytes (16) . However, because CD81 associates with specific complexes on different cell lineages (12) , it is likely that CD81 promotes cell-type-restricted signaling events that might or might not require multiple ligands or receptor cross-linking. Data are shown as percentage of CD19 cells expressing the markers indicated on the left (mean Ϯ SD). * , Healthy donors (n ϭ 21); †, HCV-infected patients with cryoglobulinemia (n ϭ 26); ‡, HCV-infected patients (n ϭ 38); §, HBV-infected patients (n ϭ 16); †, ‡, characteristics of patients are summarized in Table 3 . HBV, hepatitis B virus. CD81 has very short cytoplasmic regions without any recognizable signaling motif and is believed to signal through interaction with associated partners. CD19 directly binds to CD81, representing an obvious candidate to exert such a function (25) . Our data, showing that CD19 is not activated during CD81 engagement, argue against this hypothesis. Other proteins interacting with CD81 on the B cell surface, namely integrin ␣4␤1 and MHC-II, have been identified (26, 27) , but more work is required to assess whether these proteins play any role in CD81-mediated B cell activation. We have found that CD81 engagement activates the JNK pathway through a mechanism that, at variance with the BCR-dependent JNK activation, is not associated with general tyrosine phosphorylation, as detected by Western blot. The finding that the CD81 signaling pathway diverges from the BCR pathway upstream of JNK activation might reveal new targets for the treatment of lymphoproliferative diseases resulting from uncontrolled B cells stimulation.
We have found that chronic HCV infection associates in 85% of cases with a high percentage of activated B cells and that therapeutic eradication of HCV coincides with the reduction of this activated B cell phenotype. Our data demonstrate that polyclonal B cell activation is a general feature of chronic HCV infections, because B cell activation is observed regardless of the presence of mixed cryoglobulinemia. It is tempting to speculate that the polyclonal B cell activation obtained by multimeric CD81 engagement in vitro mimics what occurs in HCV-infected patients when the virus binds CD81 on the B cell surface. Notably, our model does not require the assumption that B cells are infected by HCV. Indeed, the surface contact between HCV and CD81 could activate B cells in the absence of infection. Our finding that CD81 engagement by HCV envelope protein preferentially activates naïve B lymphocyte proliferation may be relevant to explain the high rate of autoantibodies found in HCV infections (28) and the association of HCV with cryoglobulinemia (5). It is possible that the polyclonal-antigenindependent activation of naïve B cells induced by HCV engagement of CD81 is the first step toward the polyclonal expansion of autoreactive clones of naïve B cells that, by becoming memory cells, can be more readily activated in a bystander mode to produce autoantibodies (24) . In a few cases, this B cell autoreactivity, most likely in combination with still unidentified genetic͞environmental factors, could evolve into frank lymphoproliferative disorders, such as type II cryoglobulinemia (5) or non-Hodgkin lymphoma (6, 7) .
We found that the chemokine receptor CXCR3 is up-regulated on B lymphocytes activated by CD81, whereas CXCR3 is expressed at low level on B cells activated by SAC or BCR engagement. This finding correlates with an increased expression of CXCR3 on B cells derived from HCV-infected patients compared with those of healthy controls. The ligands of CXCR3 (CXCL9, CXCL10, and CXCL11) are all produced at high levels within hepatitis-C-infected liver (29) (30) (31) . B cells' migration to the liver in a CXCR3-dependent fashion together with locally produced cytokines could explain the B lymphocyte follicles frequently observed in the livers of patients with chronic HCV infection (32) . Recently, in agreement with our observations, an independent study has shown that CXCR3 is up-regulated on B cells from HCV-infected patients compared with those of healthy controls (33) .
It is possible that the HCV-CD81 interaction plays a central role for virus adaptation to the human host. We speculate that the evolutionary pressure on the compact genome of HCV virus has determined the selection of an envelope protein capable of multiple functions during infection. These activities include not only binding and entry into target cells but also the modulation of the immune system required to establish a chronic infection. The interaction with the widely distributed tetraspanin CD81, a promiscuous molecule forming different receptor complexes on different cell types, may be a multifunctional strategy for HCV to achieve multiple goals through the same envelope protein. Indeed, CD81 engagement by the HCV envelope protein inhibits NK cells (17) , costimulates T lymphocytes (16) , and activates B cells (this article). Interestingly, it has been recently reported that the engagement of B cells by purified E2 induced double-strand DNA breaks specifically in the variable region of Ig (V H ) gene locus, leading to hypermutation in the V H genes of B cells (34) . Altogether, one can depict a scenario where interaction between HCV and CD81 facilitates the establishment of chronic infection, creating an escape mechanism for the virus through the inhibition of the innate immune response and the dilution of the adaptive immune response resulting from polyclonal expansion.
